MedMira Inc. (MIR.V)
CAD 0.1
(5.56%)
CAD 0.1
(5.56%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.00 CAD | -40.74% |
| 2022 | -0.00 CAD | -170.0% |
| 2021 | -0.00 CAD | 67.74% |
| 2020 | -0.00 CAD | 3.13% |
| 2019 | -0.00 CAD | 15.79% |
| 2018 | -0.00 CAD | 5.0% |
| 2017 | -0.00 CAD | 48.72% |
| 2016 | -0.01 CAD | -34.48% |
| 2015 | -0.01 CAD | 22.67% |
| 2014 | -0.01 CAD | -650.0% |
| 2013 | -0.00 CAD | -108.33% |
| 2012 | 0.01 CAD | 153.1% |
| 2011 | -0.02 CAD | 3.83% |
| 2010 | -0.02 CAD | 48.01% |
| 2009 | -0.05 CAD | 47.26% |
| 2008 | -0.09 CAD | 14.3% |
| 2007 | -0.10 CAD | 33.33% |
| 2006 | -0.15 CAD | -7.14% |
| 2005 | -0.14 CAD | -40.0% |
| 2004 | -0.10 CAD | 44.44% |
| 2003 | -0.18 CAD | 33.33% |
| 2002 | -0.27 CAD | 22.86% |
| 2001 | -0.35 CAD | -150.0% |
| 2000 | -0.14 CAD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.00 CAD | 27.27% |
| 2024 Q1 | -0.00 CAD | 21.43% |
| 2024 Q3 | -0.00 CAD | -37.5% |
| 2023 FY | - CAD | -40.74% |
| 2023 Q3 | -0.00 CAD | -14.29% |
| 2023 Q4 | -0.00 CAD | -75.0% |
| 2023 Q2 | -0.00 CAD | 22.22% |
| 2023 Q1 | -0.00 CAD | -28.57% |
| 2022 Q2 | -0.00 CAD | 0.0% |
| 2022 Q1 | -0.00 CAD | 30.0% |
| 2022 FY | - CAD | -170.0% |
| 2022 Q4 | -0.00 CAD | -16.67% |
| 2022 Q3 | -0.00 CAD | 14.29% |
| 2021 Q3 | -0.00 CAD | 16.67% |
| 2021 Q1 | 0.00 CAD | 0.0% |
| 2021 Q2 | -0.00 CAD | -160.0% |
| 2021 Q4 | -0.00 CAD | -100.0% |
| 2021 FY | - CAD | 67.74% |
| 2020 Q2 | -0.00 CAD | -28.57% |
| 2020 Q4 | - CAD | 100.0% |
| 2020 Q1 | -0.00 CAD | 0.0% |
| 2020 Q3 | -0.00 CAD | -22.22% |
| 2020 FY | - CAD | 3.13% |
| 2019 Q1 | -0.00 CAD | 0.0% |
| 2019 FY | - CAD | 15.79% |
| 2019 Q2 | -0.00 CAD | -12.5% |
| 2019 Q3 | -0.00 CAD | 11.11% |
| 2019 Q4 | - CAD | 100.0% |
| 2018 FY | - CAD | 5.0% |
| 2018 Q1 | -0.00 CAD | 0.0% |
| 2018 Q3 | -0.00 CAD | 9.09% |
| 2018 Q2 | -0.00 CAD | -10.0% |
| 2018 Q4 | - CAD | 100.0% |
| 2017 Q4 | - CAD | 100.0% |
| 2017 Q2 | -0.00 CAD | 33.33% |
| 2017 FY | - CAD | 48.72% |
| 2017 Q1 | -0.00 CAD | 0.0% |
| 2017 Q3 | -0.00 CAD | -37.5% |
| 2016 Q1 | -0.00 CAD | 0.0% |
| 2016 Q4 | - CAD | 100.0% |
| 2016 Q3 | -0.00 CAD | -20.0% |
| 2016 FY | - CAD | -34.48% |
| 2016 Q2 | -0.00 CAD | -7.14% |
| 2015 Q1 | -0.00 CAD | 0.0% |
| 2015 FY | - CAD | 22.67% |
| 2015 Q4 | - CAD | 100.0% |
| 2015 Q3 | -0.00 CAD | 21.05% |
| 2015 Q2 | -0.00 CAD | 0.0% |
| 2014 Q1 | -0.00 CAD | 0.0% |
| 2014 FY | - CAD | -650.0% |
| 2014 Q2 | -0.00 CAD | -47.37% |
| 2014 Q3 | -0.00 CAD | 14.29% |
| 2014 Q4 | - CAD | 100.0% |
| 2013 Q3 | -0.00 CAD | -173.33% |
| 2013 Q1 | 0.00 CAD | 0.0% |
| 2013 FY | - CAD | -108.33% |
| 2013 Q2 | 0.00 CAD | 200.0% |
| 2013 Q4 | - CAD | 100.0% |
| 2012 Q4 | - CAD | 100.0% |
| 2012 Q3 | -0.01 CAD | 36.46% |
| 2012 FY | - CAD | 153.1% |
| 2012 Q1 | -0.01 CAD | 0.0% |
| 2012 Q2 | -0.01 CAD | -31.51% |
| 2011 Q1 | -0.01 CAD | 0.0% |
| 2011 Q2 | -0.01 CAD | -9.09% |
| 2011 Q3 | -0.00 CAD | 31.67% |
| 2011 FY | - CAD | 3.83% |
| 2011 Q4 | - CAD | 100.0% |
| 2010 Q1 | -0.01 CAD | 0.0% |
| 2010 FY | - CAD | 48.01% |
| 2010 Q2 | -0.00 CAD | 43.66% |
| 2010 Q3 | -0.00 CAD | 22.5% |
| 2010 Q4 | - CAD | 100.0% |
| 2009 Q4 | - CAD | 100.0% |
| 2009 Q2 | -0.01 CAD | 42.53% |
| 2009 Q1 | -0.02 CAD | 0.0% |
| 2009 FY | - CAD | 47.26% |
| 2009 Q3 | -0.01 CAD | 13.0% |
| 2008 FY | - CAD | 14.3% |
| 2008 Q3 | -0.02 CAD | -110.13% |
| 2008 Q2 | -0.01 CAD | 62.74% |
| 2008 Q1 | -0.02 CAD | 0.0% |
| 2008 Q4 | - CAD | 100.0% |
| 2007 Q4 | - CAD | 100.0% |
| 2007 Q3 | -0.02 CAD | 24.9% |
| 2007 Q2 | -0.03 CAD | -1.58% |
| 2007 Q1 | -0.03 CAD | 0.0% |
| 2007 FY | - CAD | 33.33% |
| 2006 Q2 | -0.03 CAD | 33.83% |
| 2006 Q1 | -0.04 CAD | 0.0% |
| 2006 Q3 | -0.05 CAD | -76.49% |
| 2006 Q4 | - CAD | 100.0% |
| 2006 FY | - CAD | -7.14% |
| 2005 Q4 | - CAD | 100.0% |
| 2005 Q3 | -0.03 CAD | 6.93% |
| 2005 Q2 | -0.03 CAD | -18.15% |
| 2005 Q1 | -0.03 CAD | 0.0% |
| 2005 FY | - CAD | -40.0% |
| 2004 Q2 | -0.02 CAD | -7.39% |
| 2004 Q3 | -0.03 CAD | -12.96% |
| 2004 Q1 | -0.02 CAD | 0.0% |
| 2004 FY | - CAD | 44.44% |
| 2004 Q4 | - CAD | 100.0% |
| 2003 Q1 | -0.04 CAD | 0.0% |
| 2003 FY | - CAD | 33.33% |
| 2003 Q2 | -0.05 CAD | -7.73% |
| 2003 Q3 | -0.07 CAD | -41.77% |
| 2003 Q4 | - CAD | 100.0% |
| 2002 Q3 | -0.05 CAD | -18.4% |
| 2002 Q1 | -0.06 CAD | 0.0% |
| 2002 Q4 | - CAD | 100.0% |
| 2002 FY | - CAD | 22.86% |
| 2002 Q2 | -0.05 CAD | 21.7% |
| 2001 FY | - CAD | -150.0% |
| 2000 FY | - CAD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Arch Biopartners Inc. | -0.05 CAD | 92.871% |
| Covalon Technologies Ltd. | -0.18 CAD | 97.889% |
| Hemostemix Inc. | -0.03 CAD | 87.459% |
| Universal Ibogaine Inc. | -0.06 CAD | 93.274% |
| Kane Biotech Inc. | -0.04 CAD | 89.415% |
| Marvel Biosciences Corp. | -0.06 CAD | 93.426% |
| NervGen Pharma Corp. | -0.38 CAD | 99.0% |
| XORTX Therapeutics Inc. | -1.44 CAD | 99.736% |